09/25/2017
9 Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131
RICHLAND, ...
08/31/2017
RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and ...
08/04/2017
Gross Margin Expands Significantly to 31% on Ongoing Process Improvements and Expense Reduction
RICHLAND, ...
07/07/2017
RICHLAND, Wash., July 7, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed ...
07/06/2017
Additional Testing for GammaTile™ Planned for Completion by Year-End 2017
RICHLAND, Wash., July 6, ...
06/20/2017
Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis
RICHLAND, Wash., June ...
05/03/2017
At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained
RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- ...
04/18/2017
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical ...
03/09/2017
Settlement Fully Funded by D&O Insurance
RICHLAND, Wash., March 9, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE ...
02/08/2017
Management Continues to Expect Stronger Second Half of Fiscal 2017
RICHLAND, Wash., Feb. 8, ...
12/21/2016
RICHLAND, Wash., Dec. 21, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and ...
11/30/2016
RICHLAND, Wash., Nov. 30, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and ...
[dsm_card title=”Media & Public Relations Contact” button_url_new_window=”1″ _builder_version=”4.8.1″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”||0px||false|false” hover_enabled=”0″ sticky_enabled=”0″]
If you have questions or need help, please contact:
Chuck Padala
Public and Media Relations
[/dsm_card]